Canadian Consensus Conference on Osteoporosis, 2006 Update

Journal of Obstetrics and Gynaecology Canada

Volumn 28, Issue 2, 2006, Pages S95-S112

  Brown, Jacques P ^a   Fortier, Michel ^a   Frame, Heather ^a   Lalonde, André ^a   Papaioannou, Alexandra ^a   Senikas, Vyta ^a   Yuen, Chui Kin ^a   Henneberg, Elke ^b   Capistran, Chantal ^c   Oman, Jackie ^c  

^a Communications Message and More Inc ^*  (Canada)

^b SOGC ^*  (Canada)

^c SOGC   (Canada)

Author keywords

Anabolic; Antiresorptive; Bisphosphonates; Bone forming agent; Bone mineral density; Bone turnover markers; Calcitonin; Diagnosis; Dual energy X ray absorptiometry; Fragility fractures; Hormone therapy; Osteoporosis; Prevention; Selective estrogen receptor modulator; Treatment; Vertebral fractures

Indexed keywords

ALENDRONIC ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ETIDRONIC ACID; PARATHYROID HORMONE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D;

ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE RADIOGRAPHY; BONE TURNOVER; CANADA; CLINICAL EFFECTIVENESS; DATA ANALYSIS; DIARRHEA; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; FRAGILITY FRACTURE; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; NAUSEA; NUTRITIONAL ASSESSMENT; OSTEOMALACIA; OUTCOME ASSESSMENT; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PREVALENCE; PROFESSIONAL KNOWLEDGE; QUALITY CONTROL; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; FEMALE; OSTEOPOROSIS;

FEMALE; HUMANS; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES;

EID: 46049097498     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)32087-4     Document Type: Article

References (135)

1. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993, 94:646-650.
2. Papadimitropoulos E.A., Coyte P.C., Josse R.G., Greenwood C.E. Current and projected rates of hip fracture in Canada. Can Med Assoc J 1997, 157:1357-1363.
3. Tenenhouse A., Joseph L., Kreiger N., Poliquin S., Murray T.M., Blondeau L., CaMos Research Group, et al. Canadian Multicentre Osteoporosis Study. Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: The Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int 2000, 11:897-904.
4. Looker A.C., Orwoll E.S., Johnston C.C., Lindsay R.L., Wahner H.W., Dunn W.L., et al. Prevalence of low femoral bone density in older US adults from NHANES III. J Bone Miner Res 1997, 12:1761-1768.
5. Hanley D.A., Josse R.G. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. Can Med Assoc J 1996, 155:921-923.
6. Jackson S.A., Tenenhouse A., Robertson L., the CaMos Study Group Vertebral fracture definition from population-based data: preliminary results from the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int 2000, 11:680-687.
7. Melton L.J.I., Chrischilles E.A., Cooper C., Lane A.W., Riggs B.L. Perspective. how many women have osteoporosis?. J Bone Miner Res 1992, 7:1005-1010.
8. Chrischilles E.A., Butler C.D., Davis C.S., Wallace R.B. A model of lifetime osteoporosis impact. Arch Intern Med 1991, 151:2026-2032.
9. Cauley J.A., Thompson D.E., Ensrud K.C., Scott J.C., Black D.M. Risk of mortality following clinical fractures. Osteoporos Int 2000, 11:556-561.
10. Cooper C., Atkinson E.J., Jacobsen S.J., O'Fallon W.M., Melton L.J. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993, 137:1001-1005.
11. Center J.R., Nguyen T.V., Schneider D., Sambrook P.N., Eisman J.A. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999, 353:878-882.
12. Cooper C., Atkinson E.J., O'Fallon W.M., Melton L.J. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 1992, 7:221-227.
13. Gold D.T. The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone 1996, 18:185S-189S.
14. Wiktorowicz M.E., Goeree R., Papaioannou A., Adachi J.D., Papadimitropoulos E. Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos Int 2001, 12:271-278.
15. Shea B., Wells G., Cranney A., Zytaruk N., Robinson V., Griffith L., et al. Osteoporosis Methodology Group. Osteoporosis Research Advisory Group. Calcium supplementation on bone loss in postmenopausal women. Cochrane Database Syst Rev 2004, 1. CD004526. Review.
16. McCabe L.D., Martin B.R., McCabe G.P., Johnston C.C., Weaver C.M., Peacock M. Dairy intakes affect bone density in the elderly. Am J Clin Nutr 2004, 80(4):1066-1074.
17. Heaney R.P., Dowell S.D., Bierman J., Hale C.A., Bendich A. Absorbability and cost effectiveness in calcium supplementation. J Am Coll Nutr 2001, 20(3):239-246.
18. Papadimitropoulos E., Wells G., Shea B., Gillespie W., Weaver B., Zytaruk N., et al. Meta-analyses of therapies for postmenopausal osteoporosis. VIII: meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 2002, 23:560-569.
19. 3 -cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomized double blind controlled trial. BMJ 2003, 326:469-472.
20. 3) for prevention of fractures in primary care. BMJ 2005, 330:1003-1006.
21. 3 and calcium for the secondary prevention of low-trauma fractures in elderly people -randomised evaluation of calcium or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 2005, 6736:63013-63019.
22. Smith E.L. The role of exercise in the prevention and treatment of osteoporosis [review]. Tap Geriatr Rehab 1995, 10:55-63.
23. Jaglal S.B., Kreiger N., Darlington G. Past and recent physical activity and risk of hip fracture. Am J Epidemiol 1993, 138:107-118.
24. Kerr D.A., Prince R.L., Morton A., Dick I. Does high resistance weight training have a greater effect on bone mass than low resistance weight training? [abstract, 128]. J Bone Miner Res 1994, 9(suppl 1):S152.
25. Dalsky G.P., Stocke K.S., Ehsani A.A., Slatopolsky E., Lee W.C., Birge S.J. Weight-bearing exercise training and lumbar bone mineral content in postmenopausal women. Ann Intern Med 1998, 108:824-828.
26. Kelley G.A., Kelley K.S., Tran Z.V. Exercise and lumbar spine bone mineral density in postmenopausal women: a meta-analysis of individual patient data. J Gerontol A Biol Sci Med Sci 2002, 57:M599-M604.
27. Chan K., Qin L., Lau M., Woo J., Au S., Choy W., et al. A randomized, prospective study of the effects of Tai Chi Chun exercise on bone mineral density in postmenopausal women. Arch Phys Med Rehabil 2004, 85:717-722.
28. Bonaiuti D., Shea B., Iovine R., Negrini S., Robinson V., Kemper H.C., et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 2002, 3. CD000333. Review.
29. Carter N.D., Khan K.M., McKay H.A., Petit M.A., Waterman C., Heinonen A. Community-based exercise program reduces risk factors for falls in 65-to 75-year-old women with osteoporosis: randomized controlled trial. Can Med Assoc J 2002, 167(9):997-1004. Erratum in: Can Med Assoc J 2003;168(2):152.
30. Munger R.G., Cerhan J.R., Chiu B.C.-H. Prospective study of dietary protein intake and risk of hip fracture in postmenopausal women. Am J Clin Nutr 1999, 69:147-152.
31. Kanis J.A., Borgstrom F., De Laet C., Johansson H., Johnell O., Jonsson B., et al. Assessment of fracture risk. Osteoporos Int 2005, 16(6):581-589. Epub 2004 Dec 23.
32. Hampson G., Martin F.C., Moffat K., Vaja S., Sankaralingam S., Cheung J., et al. Effects of dietary improvement on bone metabolism in elderly underweight women with osteoporosis: a randomised controlled trial. Osteoporos Int 2003, 14(9):750-756. Epub 2003 Aug 5.
33. Harrington M., Bennett T., Jakobsen J., Ovesen L., Brot C., Flynn A., et al. Effect of a high-protein, high-salt diet on calcium and bone metabolism in postmenopausal women stratified by hormone replacement therapy use. Eur J Clin Nutr 2004, 58(10):1436-1439.
34. Cifuentes M., Riedt C.S., Brolin R.E., Field M.P., Sherrell R.M., Shapses S.A. Weight loss and calcium intake influence calcium absorption in overweight postmenopausal women. Am J Clin Nutr 2004, 80(1):123-130.
35. Kiel D.P., Felson D.T., Hannan M.T., Anderson J.J., Wilson P.W.F. Caffeine and the risk of hip fracture: the Framingham study. Am J Epidem 1990, 132(4):675-684.
36. Oncken C., Prestwood K., Cooney J.L., Unson C., Fall P., Kulldorff M., et al. Effects of smoking cessation or reduction on hormone profiles and bone turnover in postmenopausal women. Nicotine Tob Res 2002, 4(4):451-458.
37. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical report series 1994, WHO, Geneva.
38. No authors listed. Osteoporosis Prevention, Diagnosis, and Therapy. NIH Consensus Statement Online 2000 March 27-29;17(1):1-36. Accessed on Dec. 2nd, 2005. http://consensus.nih.gov/2000/2000Osteoporosis111html.htm.
39. Brown J.P., Josse R.G., for the Scientific Advisory Council of the Osteoporosis Society of Canada 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J 2002, 167:S1-S36.
40. Siminoski K., Leslie W.D., Frame H., Hodsman A., Josse R.G., Khan A., et al. Recommendations for bone mineral density reporting in Canada. Can Assoc Radiol J 2005, 56(3):178-188.
41. Ungar W.J., Josse R., Lee S., Ryan N., Adachi R., Hanley D., et al. The Canadian SCORE questionnaire: optimizing the use of technology for low bone density assessment. Simple Calculated Osteoporosis Risk Estimate. J Clin Densitom 2000, 3:269-280.
42. Cadarette S.M., Jaglal S.B., Kreiger N., McIsaac W.J., Darlington G.A., Tu J.V. Development and validation of the osteoporosis risk assessment instrument to facilitate selection of women for bone densitometry. Can Med Assoc J 2000, 162:1289-1294.
43. National Osteoporosis Foundation. Osteoporosis: review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis. Osteoporos Int 1998, 8(Suppl 4):7-80.
44. Cadarette S.M., Jaglal S.B., Murray T.M., McIsaac W.J., Joseph L., Brown J.P. Evaluation of decision rules for referring women for bone densitometry by dual-energy X-ray absorptiometry. J Am Med Assoc 2001, 286:57-63.
45. Geusens P., Hochberg M.C., van der Voort D.J., Pols H., van der Klift M., Siris E., et al. Performance of risk indices for identifying low bone density in postmenopausal women. Mayo Clin Proc 2002, 77:629-637.
46. Cadarette S.M., McIsaac W.J., Hawker G.A., Jaakkimainen L., Culbert A., Zarifa G., et al. The validity of decision rules for selecting women with primary osteoporosis for bone mineral density testing. Osteoporos Int 2004, 15:361-366.
47. Richy F., Gourlay M., Ross P.D., Sen S.S., Radican L., De Ceulaer F., et al. Validation and comparative evaluation of the osteoporosis self-assessment tool -OST) in a Caucasian population from Belgium. Q J Med 2004, 97:39-46.
48. Hajcsar E.E., Hawker G., Bogoch E.R. Investigation and treatment of osteoporosis in patients with fragility fracture. Can Med Assoc J 2000, 163:819-822.
49. Papaioannou A., Giangregorio L., Kvern B., Boulos P., Ioannidis G., Adachi J.D. The osteoporosis care gap in Canada. BMC Musculoskelet Disord 2004, 5(1):11.
50. Ingle B.M., Eastell R. Site-specific bone measurements in patients with ankle fracture. Osteoporos Int 2002, 13:342-347.
51. Jacobsen D., Sargent J., Atkinson E.J., O'Fallon W.M., Melton L.J.I. Contribution of weather to the seasonality of distal forearm fractures: a population-based study in Rochester, Minnesota. Osteoporos Int 1999, 9:254-259.
52. Tromp A.M., Smit J.H., Deeg D.J.H., Bouter L.M., Lips P. Predictors for falls and fractures in longitudinal aging study Amsterdam. J Bone Miner Res 1998, 13:1932-1939.
53. Kannus P., Palvanen M., Niemi S., Parkkari J., Jarvinen M. Epidemiology of Osteoporotic Pelvic Fractures in Elderly People in Finland: Sharp Increase in 1970-1997 and alarming projections for the new millennium. Osteoporos Int 2000, 11:443-448.
54. Kanis J.A., Oden A., Johnell O., Jonsson B., de Laet C., Dawson A. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 2001, 12:417-427.
55. Khan S.A., de Geus C., Holroyd B., Russell A.S. Osteoporosis follow-up after wrist fractures following minor trauma. Arch Intern Med 2001, 161:1309-1312.
56. Siminoski K., Jiang G., Adachi J.D., Hanley D.A., Cline G., Ioannidis G., et al. Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures. Osteoporos Int 2005, 16(4):403-410. Epub 2004 Aug 11.
57. Klotzbuecher C.M., Ross P.D., Landsman P.B., Abbott T.A.I., Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000, 15:721-739.
58. Khan A.A., Brown J.P., Kendler D.L., Leslie W.D., Lentle B.C., Lewiecki E.M., et al. The 2002 Canadian bone densitometry recommendations: take-home messages. Can Med Assoc J 2002, 167(10):1141-1145.
59. Bauer D.C., Gluer C.C., Cauley J.A., Vogt T.M., Ensrud K.E., Genant H.K., et al. Broadband ultrasound attenuation predicts fractures strongly and independently of densitometry in older women. A prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1997, 157:629-634.
60. Hans D., Dargent-Molina P., Schott A.M., Sebert J.L., Cormier C., Kotzki P.O., et al. Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study. Lancet 1996, 348:511-514.
61. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. J Am Med Assoc 1999, 282(7):637-645.
62. Lindsay R., Silverman S.L., Cooper C., Hanley D.A., Barton I., Broy S.B., et al. Risk of new fracture in the year following a fracture. J Am Med Assoc 2001, 285:320-323.
63. Black D.M., Arden N.K., Palarmo L., Pearson J., Cummings S.R. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1999, 14:821-828.
64. National Osteoporosis Foundation Working Group on Vertebral Fractures Assessing vertebral fractures. J Bone Miner Res 1995, 10:518-523.
65. Miller P.D., Baran D.T., Bilezikian J.P., Greenspan S.L., Lindsay R., Riggs B.L., et al. Practical clinical application of biochemical markers of bone turnover: consensus of an expert panel. J Clin Densitom 1999, 2(3):323-342.
66. Garnero P., Hausherr E., Chapuy M.C., Marcelli C., Grandjean H., Muller C., et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res 1996, 11(10):1531-1538.
67. Looker A.C., Bauer D.C., Chesnut C.H.I., Gundberg M., Hochberg M.C., Kleerekoper M., et al. Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int 2000, 11:467-480.
68. Delmas P.D., Eastell R., Garnero P., Seibel M.J., Stepan J., for the Committee of Scientific Advisors of the International Osteoporosis Foundation The use of biochemical markers of bone turnover in Osteoporosis. Osteoporos Int 2000, (Suppl 6):S2-S17.
69. Eastell R., Barton I., Hannon R.A., Chines A., Garnero P., Delmas P.D. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003, 18(6):1051-1056.
70. Nishizawa Y., Nakamura T., Ohta H., Kushida K., Gorai I., Shiraki M., et al. Guidelines for the use of biochemical markers of bone turnover in osteoporosis -2004). J Bone Miner Metab 2005, 23:97-104.
71. Garnero P., Bianchi F., Cartier M.-C., Genty V., Jacob N., Karmel S., et al. Les marqueurs biologiques du remodelage osseux: variations pré-analytiques et recommandations pour leur utilisation. Annales de Biologie Clinique 2000, 58(6):683-704.
72. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. J Am Med Assoc 2002, 288:321-333.
73. Writing Group for the Women-s Health Initiative Investigators. J Am Med Assoc 2004, 291:1701-1712.
74. Blake J.M., Collins J.A., Reid R.L., Fedorkow D.M., Lalonde A.B. The SOGC statement on the WHI report on estrogen and progestin use in postmenopausal women. J Obstet Gynaecol Can 2002, 24:783-790.
75. NAMS Board of Trustees. Recommendations for estrogen and progestogen use in peri- and postmenopausal women: October 2004 position statement of The North American Menopause Society. Menopause 2004, 11:589-600.
76. Bhavnani B.R., Strickler R.C. Menopausal hormone therapy. J Obstet Gynaecol Can 2005, 27:137-162.
77. Ettinger B., Genant H.K., Cann C.E. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985, 102:319-324.
78. Nachtigall L.E., Nachtigall R.H., Nachtigall R.D., Beckman E.M. Estrogen replacement therapy I: a 10-year prospective study in the relationship to osteoporosis. Obstet Gynecol 1979, 53:277-281.
79. Lufkin E.G., Wahner H.W., O'Fallon W.M., Hodgson S.F., Kotowica M.A., Lane A.W., et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992, 117:1-9.
80. Genant H.K., Lucas J., Weiss S., Akin M., Emkey R., McNaney-Flint H., et al. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. Arch Intern Med 1997, 157:2609-2615.
81. Ettinger B., Ensrud K.E., Wallace R., Johnson K.C., Cummings S.R., Yankov V., et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 2004, 104:443-451.
82. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. J Am Med Assoc 1999, 282:637-645.
83. Lufkin E.G., Wong M., Deal C. The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis. Rheum Dis Clin North Am 2001, 27:163-185. vii.
84. Delmas P.D., Ensrud K.E., Adachi J.D., Harper K.D., Sarkar S., Gennari C., et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002, 87(8):3609-3617.
85. Maricic M., Adachi J.D., Sarkar S., Wu W., Wong M., Harper K.D. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002, 162(10):1140-1143.
86. Delmas P.D., Genant H.K., Crans G.G., Stock J.L., Wong M., Siris E., et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003, 33(4):522-532.
87. Kanis J.A., Johnell O., Black D.M., Downs R.W., Sarkar S., Fuerst T., et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 2003, 33(3):293-300.
88. Cranney A., Guyatt G., Griffith L., Wells G., Tugwell P., Rosen C. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002, 23:570-578.
89. Jolly E.E., Bjarnason N.H., Neven P., Plouffe L., Johnston C.C., Watts S.D., et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 2003, 10(4):337-344.
90. Cauley J.A., Norton L., Lippman M.E., Eckert S., Krueger K.A., Purdie D.W., et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001, 65(2):125-134.
91. Martino S., Cauley J.A., Barrett-Connor E., Powles T.J., Mershon J., Disch D. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004, 96:1751-1761.
92. Barrett-Connor E., Grady D., Sashegyi A., Anderson P.W., Cox D.A., Hoszowski K., et al. for the MORE Investigators. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: 4-year results from the MORE -Multiple Outcomes of Raloxifene Evaluation) Randomized Trial. J Am Med Assoc 2002, 287:847-857.
93. Grady D., Wenger N.K., Herrington D., Khan S., Furberg C., Hunninghake D., et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the heart and estrogen/progestin replacement study. Ann Int Med 2000, 132(9):689-696.
94. Fisher B., Costantino J.P., Wickherham D.L., Redmond C.K., Kavanah M., Cronin W.M. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998, 90:1371-1388.
95. Mathoo J.M., Cranney A., Papaioannou A., Adachi J.D. Rational use of oral bisphosphonates for the treatment of osteoporosis. Curr Osteoporos Rep 2004, 2:17-23.
96. Cranney A., Guyatt G., Krolicki N., Welch V., Griffith L., Adachi J.D., et al. Osteoporosis Research Advisory Group -ORAG). A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int 2001, 12:140-151.
97. Cranney A., Wells G., Willan A., Griffith L., Zytaruk N., Robinson V., et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002, 23:508-516.
98. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996, 348(9041):1535-1541.
99. Black D.M., Thompson D.E., Bauer D.C., Ensrud K., Musliner T., Hochberg M.C. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial -FIT) Research Group. J Clin Endocrinol Metab 2000, 85:4118-4124.
100. Quandt S.A., Thompson D.E., Schneider D.L., Nevitt M.C., Black D.M. Fracture Intervention Trial Research Group. Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of -1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc 2005, 80:343-349.
101. Tonino R.P., Meunier P.J., Emkey R., Rodriguez-Portales J.A., Menkes C.J., Wasnich R.D., et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2000, 85:3109-3115.
102. Cranney A., Tugwell P., Adachi J., Weaver B., Zytaruk N., Papaioannou A., et al. Meta-analyses of therapies for postmenopausal osteoporosis. III. meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002, 23:517-523.
103. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy -VERT) Study Group. J Am Med Assoc 1999, 282(14):1344-1352.
104. Reginster J.-Y., Minne H.W., Sorensen O.H., Hooper M., Roux C., Brandi M.L., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000, 11(1):83-91.
105. Heaney R.P., Zizic T.M., Fogelman I., Olszynski W.P., Geusens P., Kasibhatla C., et al. Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporos Int 2002, 13:501-505.
106. Harrington J.T., Ste-Marie L.G., Brandi M.L., Civitelli R., Fardellone P., Grauer A., et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004, 74:129-135. Epub 2003 Dec 5.
107. Roux C., Seeman E., Eastell R., Adachi J., Jackson R.D., Felsenberg D., et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 2004, 20(4):433-439.
108. Sorensen O.H., Crawford G.M., Mulder H., Hosking D.J., Gennari C., Mellstrom D., et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003, 32(2):120-126.
109. Mellstrom D.D., Sorensen O.H., Goemaere S., Roux C., Johnson T.D., Chines A.A. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004, 75:462-468. Epub 2004 Oct 7.
110. McClung M.R., Geusens P., Miller P.D., Zippel H., Bensen W.G., Roux C., et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001, 344:333-340.
111. Bauer D.C., Black D., Ensrud K., Thompson D., Hochberg M., Nevitt M., et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 2000, 160:517-525.
112. Taggart H., Bolognese M.A., Lindsay R., Ettinger M.P., Mulder H., Josse R.G., et al. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 2002, 77:262-270.
113. Schnitzer T., Bone H.G., Crepaldi G., Adami S., McClung M., Kiel D. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging -Milano 2000, 12:1-12.
114. Rizzoli R., Greenspan S.L., Bone G., Schnitzer T.J., Watts N.B., Adami S., et al. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002, 17:1988-1996.
115. Brown J.P., Kendler D.L., McClung M.R., Emkey R.D., Adachi J.D., Bolognese M.A., et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002, 71:103-111. Epub 2002 Jun 27.
116. Papaioannou A., Ioannidis G., Adachi J.D., Sebaldt R.J., Ferko N., Puglia M., et al. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 2003, 14:808-813. Epub 2003 Sep 11.
117. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone -1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
118. Jiang Y., Zhao J.J., Mitlak B.H., Wang O., Genant H.K., Eriksen E.F. Recombinant human parathyroid hormone -1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003, 18:1932-1941.
119. Borah B., Dufresne T.E., Chmielewski P.A., Johnson T.D., Chines A., Manhart M.D. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 2004, 34:736-746.
120. Vahle J.L., Sato M., Long G.G., Young J.K., Francis P.C., Engelhardt J.A., et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone -1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002, 30:312-321.
121. Lindsay R., Cosman F., Lobo R.A., Walsh B.W., Harris S.T., Reagan J.E. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 1999, 84:3076-3081.
122. Wimalawansa S.J. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am J Med 1995, 99:36-42.
123. Delmas P.D., Vergnaud P., Arlot M.E., Pastoureau P., Meunier P.J., Nilssen M.H.L. The anabolic effect of human PTH -1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate - is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodelling system?. Bone 1995, 16:603-610.
124. Rittmaster R.S., Bolognese M., Ettinger M.P., Hanley D.A., Hodsman A.B., Kendler D.L., et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000, 85:2129-2134.
125. Cosman F., Nieves J., Woelfert L., Formica C., Gordon S., Shen V., et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001, 16:925-931.
126. Reeve J., Bradbeer J.N., Arlot M., Davies U.M., Green J.R., Hampton L., et al. hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic and histological responses. Osteoporosis Int 1991, 1:162-170.
127. Ettinger B., San Martin J.A., Crans G.G., Pavo I. Differential effects of Teriparatide after treatment with raloxifene or alendronate. J Bone Miner Res 2004, 19:745-751.
128. Roe E.B., Sanchez S.D., Cann C.E., del Puerto G.A., Pierini E., Arnaud C.D. PTH-induced increases in bone density are preserved with estrogen: results from a follow-up year in postmenopausal osteoporosis [abstract]. J Bone Miner Res 2000, 15:S193.
129. Chesnut C.H., Silverman S., Andriano K., Genant G., Gimona A., Harris S., et al. A randomized trial of nasal spray salmon calcitonin in post-menopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000, 109:267-276.
130. Faulkner K.G. The tale of the T-score: review and perspective. Osteoporos Int 2005, 16:347-352.
131. Siris E.S., Chen Y.-T., Abbott T.A., Barrett-Connor Miller P.D., Wehren L.E., Berger M.L. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 2004, 164:1108-1112.
132. Kanis J.A., Johnell O., Oden A., Dawson A., De Laet C., Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001, 12:989-995.
133. Ste-Marie L., Sod E., Johnson T., Chines A. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. Calcif Tissue Int 2004, 75:469-476.
134. Bone H.G., Hosking D., Devogelaer J.P., Tucci J.R., Emkey R.D., Tonino R.P., et al. Ten years- experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350(12):1189-1199.
135. Yates J., Barrett-Connor E., Barlas S., Chen Y.T., Miller P.D. Siris. Rapid loss of hip fracture after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstet Gynecol 2004, 103(3):440-446.